Replies to post #11977 on AEterna Zentaris Inc. (AEZS)

[chmcnfunds]

STICKY FACT CHECK. Sticky has many erroneous statements. A few from the prior sticky have been corrected but these remain. Here are the bolded checks that are the most glaring. If you agree, feel free to re-post this information. Time to have this sticky updated.

Btw final phase 3 results for ZopTec in endometrial cancer wi be released by the end of 2016.

Expected to be completed by the end of 2016. Results likely later sometime in 2017 and AEZS known for being late in announcing results.

AEZS is now officially a US based company with an extra office in Germany

Not officially -- may want to wait until the company announces later this year.


Price estimate on this excellent news:
$.50-$1.23
.50= 300 million dollar market cap based on max diluted shares after warrant conversion and on the Adam Feuerstein biotech oncology rule that biotech firms should be valued at least 300 million dollar before the final FDA approval comes

300 million market cap WRONG. Misunderstanding of the Feuerstein-Reitan Rule. Has nothing to do with determining price estimates. Rather it establishes the minimal market cap for a company to to be successful. So AEZS, with a current market cap of approximately $14M-$16M, based on ihub detailed quote, Finviz and Google Finance, according to this “rule” has little chance for success. More on the F-R Rule:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116949306

1.23=consensus price target of 6 analysts

There are not six analysts who have a consensus target of 1.23. I challenge you to name them and provide a link.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117565259

The company has sufficient cash until February2017

While true they have cash until February, 2017 it is hardly “sufficient”. They will be down to 0 cash which would severely restrict them. Historically AEZS does an offering whenever cash gets down to about $35M.

Finally, left unsaid is the fact they are facing Nasdaq delisting and are expected to respond to this by mid November by doing a reverse split. Expect an offering after that.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117417542

(I have no shares)

AEZS

[chmcnfunds]

Help in understanding the Feuerstein-Ratain Rule. You keep using it to support your price estimate. Has nothing to do with predicting price. Establishes a market cap necessary to gain approval of cancer drugs. In this article it predicted successfully the failure of AEZS' last Phase III:


_____________________________________________________________
Will the Feuerstein-Ratain Rule Hold in 2013?
By Maxx Chatsko | More Articles
January 18, 2013 | Comments (14)

Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...
Click Here Now
Although the ranks of extremist biotech investors don't like to admit it, the Feuerstein-Ratain Rule has a perfect record when predicting micro-cap phase 3 oncology trial success. The rule is named after Adam Feuerstein, a senior columnist at TheStreet.com, and Dr. Mark Ratain, an oncologist from the University of Chicago, who published a study in JNCI in October 2011 explaining their observations. After looking at the outcomes of 58 phase 3 cancer trials over the past 10 years, the pair found that companies with a market cap less than $300 million several months before the release of trial results were 0-for-21, whereas companies with a market cap exceeding $1 billion were a respectable 21-for-27. Ouch.

The study opened the door for fierce battles every time a micro-cap biotech challenges the rule. Unfortunately for the bandwidth limits of message boards, there is at least one phase 3 trial expected to test the Feuerstein-Ratain Rule in 2013. Does the rule have any validity? Should investors jump ship and take their gains with them or hang on for an even bigger possible gain?

Passing the test
The rule was tested for the first time last year when Keryx Biopharmaceuticals (NASDAQ: KERX ) and Aeterna Zentaris (NASDAQ: AEZS ) conducted the X-PECT phase 3 trial for the drug perifosine in colorectal cancer. Despite the company botching the phase 2 trial design (which still got the nod from the Food and Drug Administration) and evaluating results from only 38 patients (of an enrollment target of 381), Keryx faithfuls stood behind the company, hoping to realize huge gains on successful phase 3 results. Those results never came. After months of delays, the companies finally announced a disappointing end to the 468 patient study that failed to meet its primary endpoint.

On April 2, shares of Keryx and Aeterna fell by more than 60%. The Feuerstein-Ratain Rule successfully predicted the outcome of its first post-JNCI trial, and their track record became a perfect 22 for 22.

Nonetheless, Aeterna is determined to forge ahead with plans for a phase 3 trial treating multiple myeloma patients with perifosine, which could challenge the rule again in 2014 or 2015.

Why the rule works
Arguments against the Feuerstein-Ratain Rule try to find fault in its simplicity. Investors often ask, "How does market cap have anything to do with the science behind the therapy?" At first glance, the two are seemingly disconnected. But Feuerstein offers a concrete explanation:

"Ratain and I recognized that one reason micro-cap cancer drugs had a perfectly dismal record with phase III trials is because the drugs being developed had already been vetted by both the market (i.e., investors) and larger, more successful cancer drug companies and found to have a low probability of success.
Cancer drugs are scarce and valuable commodities. Larger drug companies are way more likely to acquire, or at least partner with, a smaller drug company if that smaller company has a cancer drug in development with a strong shot at being successful.
Market cap, therefore, becomes a reliable and accurate proxy for predicting cancer drug trial outcomes."
Let's go through that. Feuerstein maintains that should a cancer drug have a reasonable shot at success, a larger company will acknowledge, acquire, or partner with the owner of the molecule (a micro-cap biotech, in our case) long before the 120-day threshold. It appears that market cap has everything to do with the science behind the drug.
____________________________________________________
http://www.fool.com/investing/general/2013/01/18/will-the-feuerstein-ratain-rule-hold-in.aspx

(I have no shares)

AEZS

[chmcnfunds]

STICKY FACT CHECK. Sticky has many erroneous statements. A few from the prior sticky have been corrected but these remain. Here are the bolded checks that are the most glaring. If you agree, feel free to re-post this information. Time to have this sticky updated.

Btw final phase 3 results for ZopTec in endometrial cancer wi be released by the end of 2016.

Expected to be completed by the end of 2016. Results likely later sometime in 2017 and AEZS known for being late in announcing results.

AEZS is now officially a US based company with an extra office in Germany

Not officially -- may want to wait until the company announces later this year.

Price estimate on this excellent news:
$.50-$1.23
.50= 300 million dollar market cap based on max diluted shares after warrant conversion and on the Adam Feuerstein biotech oncology rule that biotech firms should be valued at least 300 million dollar before the final FDA approval comes

300 million market cap WRONG. Misunderstanding of the Feuerstein-Reitan Rule. Has nothing to do with determining price estimates. Rather it establishes the minimal market cap for a company to to be successful. So AEZS, with a current market cap of approximately $14M-$16M, based on ihub detailed quote, Finviz and Google Finance, according to this “rule” has little chance for success. More on the F-R Rule:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116949306

1.23=consensus price target of 6 analysts

There are not six analysts who have a consensus target of 1.23. I challenge you to name them and provide a link.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117565259

The company has sufficient cash until February2017

While true they have cash until February, 2017 it is hardly “sufficient”. They will be down to 0 cash which would severely restrict them. Historically AEZS does an offering whenever cash gets down to about $35M.

Finally, left unsaid is the fact they are facing Nasdaq delisting and are expected to respond to this by mid November by doing a reverse split. Expect an offering after that.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117417542

(I have no shares)

AEZS